This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carling, T. Articles by Åkerström, G. Search for Related Content PubMed PubMed Citation Articles by Carling, T. Articles by Åkerström, G.

Reduced Parathyroid Vitamin D Receptor Messenger Ribonucleic Acid Levels in Primary and Secondary Hyperparathyroidism¹

Endocrine Surgery Unit, Department of Surgery, Uppsala University Hospital, S-751 85 Uppsala, Sweden

Address correspondence and requests for reprints to: Tobias Carling, Ph.D., M.D., Endocrine Surgery Unit, Department of Surgery, Uppsala University Hospital, S-751 85 Uppsala, Sweden. E-mail: Tobias.Carling{at}kirurgi.uu.se

Vitamin D, via its receptor (VDR), inhibits the hormone secretion and proliferation of parathyroid cells. Vitamin D deficiency and reduced parathyroid VDR expression has been associated with development of hyperparathyroidism (HPT) secondary to uremia. VDR polymorphisms may influence VDR messenger RNA (mRNA) levels and have been coupled to an increased risk of parathyroid adenoma of primary HPT. VDR mRNA relative to glyceraldehyde-3-phosphate dehydrogenase mRNA levels were determined by RNase protection assay in 42 single parathyroid adenomas of patients with primary HPT, 23 hyperplastic glands of eight patients with uremic HPT, and 15 normal human parathyroid glands. The adenomas and hyperplasias demonstrated similar VDR mRNA levels, which were reduced (42 ± 2.8% and 44 ± 4.0%) compared with the normal glands (P < 0.0001). Comparison of parathyroid adenoma with a normal-sized parathyroid gland of the same individual (n = 3 pairs) showed a 20–58% reduction in the tumor. Nodularly enlarged glands represent a more advanced form of secondary HPT and showed greater reduction in the VDR mRNA levels than the diffusely enlarged glands (P < 0.005). The reduced VDR expression is likely to impair the 1,25(OH)₂D₃-mediated control of parathyroid functions, and to be of importance for the pathogenesis of not only uremic but also primary HPT. Circulating factors like calcium, PTH, and 1,25(OH)₂D₃ seem to be less likely candidates mediating the decreased VDR gene expression in HPT.

This article has been cited by other articles:

				P. Bjorklund, T. Krajisnik, G. Akerstrom, G. Westin, and T. E. Larsson Type I Membrane Klotho Expression Is Decreased and Inversely Correlated to Serum Calcium in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4152 - 4157. [Abstract] [Full Text] [PDF]

				T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF]

				H. Takeuchi, N. C. Greep, D. S. B. Hoon, A. E. Giuliano, N. M. Hansen, N. Umetani, and F. R. Singer Hypermethylation of Adenosine Triphosphate-Binding Cassette Transporter Genes in Primary Hyperparathyroidism and Its Effect on Sestamibi Imaging J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1785 - 1790. [Abstract] [Full Text] [PDF]

				I.-L. Nilsson, J. Zedenius, L. Yin, and A. Ekbom The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy Endocr. Relat. Cancer, March 1, 2007; 14(1): 135 - 140. [Abstract] [Full Text] [PDF]

				E. H. Samander and A. Arnold Mutational Analysis of the Vitamin D Receptor Does Not Support Its Candidacy as a Tumor Suppressor Gene in Parathyroid Adenomas J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5019 - 5021. [Abstract] [Full Text] [PDF]

				B Moosgaard, P Vestergaard, L Heickendorff, F Melsen, P Christiansen, and L Mosekilde Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol., August 1, 2006; 155(2): 237 - 244. [Abstract] [Full Text] [PDF]

				S. Canadillas, A. Canalejo, R. Santamaria, M. E. Rodriguez, J. C. Estepa, A. Martin-Malo, J. Bravo, B. Ramos, E. Aguilera-Tejero, M. Rodriguez, et al. Calcium-Sensing Receptor Expression and Parathyroid Hormone Secretion in Hyperplastic Parathyroid Glands from Humans J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2190 - 2197. [Abstract] [Full Text] [PDF]

				A. Grey, J. Lucas, A. Horne, G. Gamble, J. S. Davidson, and I. R. Reid Vitamin D Repletion in Patients with Primary Hyperparathyroidism and Coexistent Vitamin D Insufficiency J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2122 - 2126. [Abstract] [Full Text] [PDF]

				L. Forsberg, E. Bjorck, J. Hashemi, J. Zedenius, A. Hoog, L.-O. Farnebo, M. Reimers, and C. Larsson Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology Eur. J. Endocrinol., March 1, 2005; 152(3): 459 - 470. [Abstract] [Full Text] [PDF]

				M. Rodriguez, E. Nemeth, and D. Martin The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism Am J Physiol Renal Physiol, February 1, 2005; 288(2): F253 - F264. [Abstract] [Full Text] [PDF]

				S Bas, E Aguilera-Tejero, A Bas, J C Estepa, I Lopez, J A Madueno, and M Rodriguez The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve J. Endocrinol., January 1, 2005; 184(1): 241 - 247. [Abstract] [Full Text] [PDF]

				N. J. Koszewski, A. P. Alimov, O.-K. Park-Sarge, and H. H. Malluche Suppression of the Human Parathyroid Hormone Promoter by Vitamin D Involves Displacement of NF-Y Binding to the Vitamin D Response Element J. Biol. Chem., October 8, 2004; 279(41): 42431 - 42437. [Abstract] [Full Text] [PDF]

				L. Canaff and G. N. Hendy Human Calcium-sensing Receptor Gene. VITAMIN D RESPONSE ELEMENTS IN PROMOTERS P1 AND P2 CONFER TRANSCRIPTIONAL RESPONSIVENESS TO 1,25-DIHYDROXYVITAMIN D J. Biol. Chem., August 9, 2002; 277(33): 30337 - 30350. [Abstract] [Full Text] [PDF]

				U. Segersten, P. Correa, M. Hewison, P. Hellman, H. Dralle, T. Carling, G. Akerstrom, and G. Westin 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase Expression in Normal and Pathological Parathyroid Glands J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2967 - 2972. [Abstract] [Full Text] [PDF]

				D. Sudhaker Rao and A. M. Parfitt Vitamin D Receptor Status in Parathyroid Adenomas J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2328 - 2328. [Full Text]

				T. Carling Vitamin D Levels and Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2328a - 2328. [Full Text]